Bacteriophage therapy 1 article

The biotechnology identity of bacteriophage therapy comes from lytic phage treatment, which places it within antibacterial phage-based therapeutic modality rather than a general field label. The defining chain runs from bacterial host specificity through phage-mediated bacterial killing to antibiotic-resistant infection therapy, while personalized phage cocktails indicates an important use case without changing the entity's core identity. Phage therapy directly uses bacteria-infecting viruses as antibacterial agents, unlike broader microbiome therapies that may alter microbial communities without phages.